| Literature DB >> 34641493 |
Jingyuan Wu1, Tuoyu Zhou2, Yinxue Wang3, Yanbiao Jiang1, Yiqing Wang1,4.
Abstract
Ovarian cancer ranks seventh in the most common malignant tumors among female disease, which seriously threatens female reproductive health. It is characterized by hidden pathogenesis, missed diagnosis, high reoccurrence rate, and poor prognosis. In clinic, the first-line treatment prioritized debulking surgery with paclitaxel-based chemotherapy. The harsh truth is that female patients are prone to relapse due to the dissemination of tumor cells and drug resistance. In these circumstances, the development of new therapy strategies combined with traditional approaches is conductive to improving the quality of treatment. Among numerous drug resources, botanical compounds have unique advantages due to their potentials in multitarget functions, long application history, and wide availability. Previous studies have revealed the therapeutic effects of bioactive plant components in ovarian cancer. These natural ingredients act as part of the initial treatment or an auxiliary option for maintenance therapy, further reducing the tumor and metastatic burden. In this review, we summarized the functions and mechanisms of natural botanical components applied in human ovarian cancer. We focused on the molecular mechanisms of cell apoptosis, autophagy, RNA and DNA lesion, ROS damage, and the multiple-drug resistance. We aim to provide a theoretical reference for in-depth drug research so as to manage ovarian cancer better in clinic.Entities:
Keywords: bioactive compounds; molecular mechanisms; natural plant products; ovarian cancer; traditional Chinese medicine
Mesh:
Substances:
Year: 2021 PMID: 34641493 PMCID: PMC8512305 DOI: 10.3390/molecules26195949
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
The antitumor effects of natural plants components in ovarian cancer.
| Compound | Classification | Model | Effect | Mechanism | Reference |
|---|---|---|---|---|---|
| Tanshinones | Terpenoid/Abietane | A-549, TOV-21G | Cytotoxic action, ROS-JNK-CHOP, PI3K/AKT/mTOR signaling pathway | Reduce cell viability, inhibit colony formation capacity | [ |
| Kadsuphilactone B | Terpenoid/Triterpene | A2780, Ishikawa cells | Cytotoxic action | Stimulate the activity of caspase-3/8/9 and MAPKs | [ |
| Methyl lucidone (ML) | Oxo Steroid | OVCAR-8, SKOV-3 | Cytotoxic action | Induce cellular apoptosis, stimulate the cleavage of caspase-3/9 | [ |
| Zeylenone (Zey) | Alicyclic | SKOV-3 | JAK2/STAT3 signaling pathway | Reduce p-JAK and p-STAT expression level | [ |
| Berbamine (BBM) | Alkaloid/Benzylisoquinoline | SKOV-3 | Wnt/β-catenin signaling pathway | Increase activity of caspase-3/9, Bax and decrease Bcl-2 levels | [ |
| Pinus massoniana bark proanthocyanidins (PMBP) | Phenol/Tannin | A-2780 | NF-κB signaling pathway | Activate mitochondria-associated apoptosis | [ |
| Sanguiin H-6 (SH-6) | Phenol/Tannin | A-2780 | MAPK signaling pathway | Increase p15/BID level, activate MAPKs (p38) | [ |
| Tetramethylpyrazine (TMP) | Alkaloid/Pyrazine | SKOV-3, OVCAR-3, A-2780 xenograft model | Suppress cell migration and invasion, reverse multiple-drug resistance (MDR) | Increase miR-211, diminish expression of proliferation and angiogenesis markers | [ |
| Dihydroartemisinin (DHA) | Terpenoid/Artemisinin | HOSEPICs | Hedgehog signaling pathway | Inhibit cell malignant behaviors and augment apoptosis | [ |
| Emodin | Quinone/Anthraquinones | A-2780, SKOV-3 | ILK/GSK- 3β/Slug signaling pathway | Diminish the levels of ILK, p-GSK-3β, β-catenin, and Slug, repress EMT | [ |
| Sulforaphane (SFN) | Ester/Isothiocyanate | Xenograft model, SKOV3-ip1, SKOV3TR-ip2 | Promote DNA and ROS damage | Protein thiols oxidation, suppress cell viability, reduce hTERT and Bcl-2 levels | [ |
| Quercetin | Flavonoid/Flavonol | SKOV-3, xenograft model | ROS-JNK-CHOP signaling pathway | Upregulate CHOP-induced DR5 expression following ROS damage | [ |
| Formononetin (FMN) | Flavonoid/Isoflavone | ES2, OV-90 | ERK1/2 signaling pathway | Upregulate caspase 3/9 and bax/bcl-2, interfere with sub G0/G1 phase arrest, increase P38 phosphorylation | [ |
| Cucurbitacin-A | Terpenoid | SKOV-3 | Trigger cell cycle arrest | DNA damage, ROS damage, MMP alterations, G2/M checkpoint | [ |
| Asiatic acid | Terpenoid/Triterpene | SKOV-3, OVCAR-3 | PI3K/Akt/mTOR signaling pathway | Downregulate phosphorylation levels of PI3K, AKT, and mTOR | [ |
| Amentoflavone (AF) | Flavonoid | Xenograft model | ROS/AMPK/mTOR signaling pathway | Downregulate the expression of Skp2 | [ |
| Proanthocyanidins (BLPs) | Phenol/Tannin | A-2780, CP70, OVCAR-3 SP stem cell | Wnt/β-catenin, AKT/mTOR/p70S6K/4E-BP-1 signaling pathway | Reduce the expression of β-catenin, induce G1 cell cycle arrest, downregulate HIF-1α and VEGF | [ |
| Scutellaria baicalensis (SB) and Fritillaria cirrhosa (FC) | Polysaccharides, Phenols, etc. | OVCA-420, OVCA-429 | NF-κB signaling pathway | Activation of caspase-3 along with downregulation of cyclins D1 and D3 | [ |
| Grifolin | Terpenoid | A-2780, SKOV-3 | AKT/mTOR/S6K signaling pathway | Upregulate autophagy markers LC3B, Atg7, Beclin-1, downregulate P62 | [ |
| Genistein | Terpenoid/sesquiterpenoid | OVCAR-3, SKOV-3 | Inhibit VEGF levels | Reduce GD3 levels and restore NKT-cell functions | [ |
| Isoliquiritigenin (ISL) | Ketone | OVCAR5, ES-2 | Suppress cell viability | Increase cleaved PARP, caspase-3 and Bax/Bcl-2 ratio; trigger G2/M cell cycle phase | [ |
| Flavonoids | Flavonoids | OVCAR-3 | Inhibit angiogenesis | Downregulate VEGF in dose-dependent manner | [ |
| Baicalin and baicalein | Flavonoid | OVCAR-3, CP-70 | Inhibit angiogenesis | Suppress cancer promoting genes including VEGF, HIF-1α, cMy-c, and NF-kB | [ |
| Harmine (HM) | Alkaloid | SKOV-3 | Inhibit cell proliferation | Inhibit both the basal and EGF-induced phosphorylation levels of ERK1/2 and CREB | [ |
| Cranberry proanthocyanidin-1 (PAC-1) | Phenol/Tannin | Chemotherapy-resistant SKOV-3, human umbilical vein endothelial cells (HUVEC) | Increase ROS generation, induce apoptosis | Block G2/M phase cell cycle progression, interfere with the phosphorylation level of VEGF-stimulated receptor | [ |
| Astragalus polysaccharide (APS) | Polysaccharide | OV-90, SKOV-3 | Inhibit proliferation and promote apoptosis | Upregulate miR-27a and FBXW7 expression levels | [ |
| Sideroxylin | Flavonoid | ES2, OV-90 | ERK1/2 signaling pathway | DNA and ROS damage, depolarize mitochondrial membrane depolarization, increase lipid peroxidation levels | [ |
| Epigallocatechin gallate (EGCG) | Flavonoid | SKOV3-ip1, SKOV3TR-ip2 | Promote DNA damage response | Suppress cell viability in time- and dose-dependent manner, reduce the expression of hTERT and Bcl-2 | [ |
| Berberine | Alkaloid | A2780, HEY, HO8910 | Promote DNA damage response | Trigger oxidative DNA damages | [ |
| Carotenoids | Terpenoid/Tetraterpenoid | Epidemiological statistics | Inhibit VEGF levels | Stimulate the activities of lymphocytes, macrophages, and cytotoxic T-cells | [ |
| Lycopene | Terpenoid | OV-MZ-6 | Diminish tumor load | Decrease expression of MMP9, ILK and EMT biomarkers | [ |
| Deoxyschizandrin | Phenol/Tannin | A-2780 | Increase ROS production | Inhibit macrophages, M2 phenotype markers CD163 and CD209 | [ |
| Curcumin | Phenol | SKOV3-ip1, HeyA8 | Reduce mean tumor growth | Decrease microvessel density, increase tumor cell apoptosis | [ |
| Procyanidin (GSP) | Phenol/Tannin | A-2780, SKOV-3 | NF-κB and MAPK/ERK pathway | Augment cytotoxicity of paclitaxel and adriamycin | [ |
Figure 1The various cellular signaling pathways of natural plants components in ovarian cancer.
Figure 2The role of molecular mechanisms in ovarian cancer.